TECH Key Statistics, Chart & Performance
The current stock price of TECH is 61.53 USD. In the past month the price decreased by -6.64%. In the past year, price decreased by -13.68%.
TECH Latest News, Press Relases and Analysis
TECH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 26.23 | 221.84B | ||
| DHR | DANAHER CORP | 29.49 | 162.82B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 182.53 | 55.39B | ||
| A | AGILENT TECHNOLOGIES INC | 27.75 | 42.88B | ||
| IQV | IQVIA HOLDINGS INC | 19.34 | 38.23B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 34.71 | 29.92B | ||
| WAT | WATERS CORP | 31.02 | 23.45B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.34 | 19.49B | ||
| ILMN | ILLUMINA INC | 28.41 | 19.04B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.39 | 16.67B | ||
| TEM | TEMPUS AI INC | N/A | 12.21B | ||
| RVTY | REVVITY INC | 20.52 | 11.41B |
Related stock screener links
About TECH
Company Profile
Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. The company is headquartered in Minneapolis, Minnesota and currently employs 3,100 full-time employees. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.
Company Info
BIO-TECHNE CORP
614 Mckinley Pl N E, Suite 1500
Minneapolis MINNESOTA 55413 US
CEO: Charles Kummeth
Employees: 3100
Phone: 16123798854
BIO-TECHNE CORP / TECH FAQ
Can you describe the business of BIO-TECHNE CORP?
Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. The company is headquartered in Minneapolis, Minnesota and currently employs 3,100 full-time employees. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.
What is the current price of TECH stock?
The current stock price of TECH is 61.53 USD. The price increased by 4.77% in the last trading session.
Does BIO-TECHNE CORP pay dividends?
BIO-TECHNE CORP (TECH) has a dividend yield of 0.54%. The yearly dividend amount is currently 0.32.
What is the ChartMill technical and fundamental rating of TECH stock?
TECH has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the sector and industry classification for BIO-TECHNE CORP?
BIO-TECHNE CORP (TECH) operates in the Health Care sector and the Life Sciences Tools & Services industry.
What is BIO-TECHNE CORP worth?
BIO-TECHNE CORP (TECH) has a market capitalization of 9.59B USD. This makes TECH a Mid Cap stock.
Can you provide the upcoming earnings date for BIO-TECHNE CORP?
BIO-TECHNE CORP (TECH) will report earnings on 2026-02-03, before the market open.
TECH Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to TECH. When comparing the yearly performance of all stocks, TECH turns out to be only a medium performer in the overall market: it outperformed 40.48% of all stocks.
TECH Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to TECH. Both the health and profitability get an excellent rating, making TECH a very profitable company, without any liquidiy or solvency issues.
TECH Financial Highlights
Over the last trailing twelve months TECH reported a non-GAAP Earnings per Share(EPS) of 1.93. The EPS increased by 7.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 6.32% | ||
| ROA | 3.04% | ||
| ROE | 3.91% | ||
| Debt/Equity | 0.15 |
TECH Forecast & Estimates
23 analysts have analysed TECH and the average price target is 70.79 USD. This implies a price increase of 15.05% is expected in the next year compared to the current price of 61.53.
For the next year, analysts expect an EPS growth of 5.89% and a revenue growth 1.85% for TECH